TriangleZanubrutinib + Tafasitamab (NCT06029309)
Zanubrutinib + Tafasitamab trial for Mantle Cell Lymphoma (NCT06029309). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with mantle cell lymphoma.
The idea: combine zanubrutinib, a daily capsule that blocks a protein called BTK, with tafasitamab, an antibody given by vein that targets CD19 on lymphoma cells.
The study looks for the right dose of the combination, then at how well it works.
This phase 1 and 2 study plans 27 patients. At the University of Miami, Alvaro Alencar leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.